A new review published in the World Allergy Organization Journal is urging a global shift in how clinical remission in allergic diseases, including systemic mastocytosis (SM), is defined and measured.
The paper argues that advances in biologics, targeted therapies and allergen immunotherapy are transforming care across allergic and inflammatory diseases, moving treatment goals beyond symptom control toward the possibility of long-term remission. However, the authors say progress has been slowed by the lack of a shared definition of what remission actually means across different conditions.
For SM specifically, the researchers note that traditionally, treatment has focused largely on symptom control. But the arrival of more effective and safer cytoreductive therapies has begun to change this landscape. Clinical trials are now establishing criteria for partial and complete remission, and these therapies are increasingly being used in selected patients with indolent SMIndolent SM A subtype of nonadvanced SM caused by the abnormal accumulation of mast cells in the bone marrow and other organs. Indolent SM accounts for around 90% of SM cases. who continue to experience significant symptoms despite optimal care.
Learn more about SM prognosis
The authors explain that partial remission in SM involves clear clinical improvement along with a major reduction in mast cellMast cell A type of white blood cell produced in the bone marrow. They help defend against infections and play a key role in allergic reactions. In SM, mast cells become overactive and build up throughout the body. burden and disease markers such as tryptaseTryptase A protein enzyme that is primarily produced by mast cells and stored in small pockets within the cells, known as granules. High levels of tryptase are a key indicator of SM.. To be considered in complete remission, an individual must have no more symptoms, normalized levels of serum tryptase, no organ involvement and no detectable neoplastic mast cells in bone marrow or tissues. The KIT D816V mutation burden in blood is also emerging as an important biomarker to track disease activity and treatment response.
Within the broader context of the review, the authors argue that clinical remission in SM should be defined by “sustained absence of clinically relevant symptoms and disease activity over time.”
“Biological markers, including serum tryptase levels and KIT D816V allele burden, should be considered supportive indicators of biological remission rather than mandatory criteria for defining clinical remission,” they continued.
The authors say that harmonized endpoints could improve research comparability, guide long-term treatment strategies and support precision medicine for SM and other allergic diseases.
Sign up here to get the latest news, perspectives, and information about SM sent directly to your inbox. Registration is free and only takes a minute.
